What is Ardelyx?
Ardelyx is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative, small-molecule medicines. The firm has established a robust market presence with the approval and launch of IBSRELA, a treatment for irritable bowel syndrome with constipation. Beyond its current commercial portfolio, Ardelyx is actively pursuing the development of XPHOZAH, a novel therapeutic candidate designed for the management of hyperphosphatemia in adult patients with chronic kidney disease on dialysis. Having successfully completed multiple Phase 3 clinical trials, the company is positioned at the intersection of high-impact scientific research and commercial execution, leveraging deep expertise in molecular biology to transform patient outcomes.
How much funding has Ardelyx raised?
Ardelyx has raised a total of $522.5M across 11 funding rounds:
Series A
$26M
Series B
$30M
Multiple Rounds
$100.8M
Share Placement
$77.8M
Stock Offering
$80.4M
Share Placement
$110M
Debt
$50M
Debt
$27.5M
Other Financing Round
$20M
Series A (2008): $26M with participation from CMEA Ventures
Series B (2011): $30M led by Amgen Business Development, CMEA Ventures, and New Enterprise Associates
Corporate Investment (2014): $15M supported by AstraZeneca
Corporate Investment (2014): $25M featuring AstraZeneca
Stock Issuance/Offering (2014): $60.8M backed by Undisclosed
Share Placement (2015): $77.8M with participation from New Enterprise Associates, Broadfin Capital, Cormorant Asset Management, Sabby Capital, Foresite Capital Management, Rock Springs Capital, and RA Capital Advisors
Stock Issuance/Offering (2016): $80.4M led by Undisclosed
Share Placement (2016): $110M supported by Perceptive Advisors, DAFNA Capital Management, RA Capital Management, EcoR1 Capital, Rock Springs Capital, First Manhattan Co., Quadrille Capital, Cormorant Asset Management, FutureFund, New Enterprise Associates, and Deerfield
Debt (2018): $50M featuring Solar Capital and Bridge Bank
Debt (2022): $27.5M backed by SLR Capital Partners
Other Financing Round (2022): $20M with participation from HealthCare Royalty Partners
Key Investors in Ardelyx
New Enterprise Associates
Established in 1977 and headquartered in Menlo Park, California, New Enterprise Associates is a venture capital firm focused on helping entrepreneurs build businesses.
Perceptive Advisors
Founded in 1999 and based in New York, NY, Perceptive Advisors is an investment firm managing around $7 billion in assets, focused on funding innovative healthcare and life sciences technologies.
RA Capital Management
RA Capital Management is a multi-stage investment manager focused on evidence-based investing in public and private healthcare and life science companies, including those developing drugs and medical devices.
What's next for Ardelyx?
With the recent influx of capital, Ardelyx is well-positioned to accelerate the commercialization of its existing assets while simultaneously advancing its clinical pipeline. The company's strategic focus remains on the successful market penetration of its approved therapies and the regulatory navigation required for its late-stage product candidates. By maintaining a disciplined approach to capital allocation and scientific rigor, Ardelyx aims to solidify its role as a leader in the renal and gastrointestinal sectors, ensuring that its innovative therapeutic solutions reach the patient populations that require them most.
See full Ardelyx company page
